Evidence map›Paper›PMID 36317881›Full record

ArticleJournal of virology2022

Activation of the Chemokine Receptor CCR1 and Preferential Recruitment of Gαi Suppress RSV Replication: Implications for Developing Novel Respiratory Syncytial Virus Treatment Strategies.

Jiao Li, Ling Xue, Jiachao Wang, Aihong Meng, Jiajun Qiao, Miao Li, Xiuli Wang, Lingtong Meng, Jingyuan Ning, Xue Gao and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jiao LiDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Ling XueDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Jiachao WangDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Aihong MengRespiratory Medicine, the Second Hospital of Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Jiajun QiaoDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Miao LiDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Xiuli WangDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Lingtong MengDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Jingyuan NingDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Xue GaoDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Wenjian LiDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Cuiqing MaDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.
Lin WeiDepartment of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical Universitygrid.256883.2, Shijiazhuang, China.ORCID 0000-0002-3265-3554
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a major pathogen that can cause acute respiratory infectious diseases of the upper and lower respiratory tract, especially in children, elderly individuals, and immunocompromised people. Generally, following viral infection, respiratory epithelial cells secrete cytokines and chemokines to recruit immune cells and initiate innate and/or adaptive immune responses. However, whether chemokines affect viral replication in nonimmune cells is rarely clear. In this study, we detected that chemokine CCL5 was highly expressed, while expression of its receptor, CCR1, was downregulated in respiratory epithelial cells after RSV infection. When we overexpressed CCR1 on respiratory epithelial cells

Indexed as

Receptors, CCR1Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsVirus ReplicationChemokinesGTP-Binding Protein alpha SubunitsHumansCCR1 protein, humanChemokinesGTP-Binding Protein alpha SubunitsReceptors, CCR1CCL5CCR1HSP90respiratory epithelial cellrespiratory syncytial virusRSV

Identifiers

PMID36317881
PMCPMC9682993
OpenAlexW4307840776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.